Abstract
Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase that belongs to the Insulin receptor subfamily involved as full length receptor in neural development. Even if the expression of ALK protein is down-regulated in the adults, the ALK full length is expressed in different types of tumors. Moreover, chromosomal rearrangements, involving the alk gene, can occur leading to the formation of different ALK fusion proteins characterized by the kinase domain of ALK fused to several partners that determine cellular localization. Structural investigation and characterization of the ALK kinase domain in absence of its crystal structure constituted the basis of development of ALK small molecule inhibitors. Here, we described normal function of the ALK receptor and its role in tumors; formation of the constitutively activated ALK fusion proteins and we reported an update of developed small molecule inhibitors of the ALK kinase activity.
Keywords: Anaplastic Lymphoma kinase (ALK), Modeling, Molecular targeting, Oncogenic fusion protein, Small molecule inhibitors, Targeted cancer therapy, tyrosine kinase, alk gene, constitutively activated ALK fusion proteins, non-Hodgkin's lymphoma, Immunohystochemical studies, pleiotrophin(PTN) and midkine (MK), histological defects, glioblastoma, breast cancer
Current Topics in Medicinal Chemistry
Title: The ALK Gene, An Attractive Target for Inhibitor Development
Volume: 11 Issue: 11
Author(s): Carmen J. Tartari, Leonardo Scapozza and Carlo Gambacorti-Passerini
Affiliation:
Keywords: Anaplastic Lymphoma kinase (ALK), Modeling, Molecular targeting, Oncogenic fusion protein, Small molecule inhibitors, Targeted cancer therapy, tyrosine kinase, alk gene, constitutively activated ALK fusion proteins, non-Hodgkin's lymphoma, Immunohystochemical studies, pleiotrophin(PTN) and midkine (MK), histological defects, glioblastoma, breast cancer
Abstract: Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase that belongs to the Insulin receptor subfamily involved as full length receptor in neural development. Even if the expression of ALK protein is down-regulated in the adults, the ALK full length is expressed in different types of tumors. Moreover, chromosomal rearrangements, involving the alk gene, can occur leading to the formation of different ALK fusion proteins characterized by the kinase domain of ALK fused to several partners that determine cellular localization. Structural investigation and characterization of the ALK kinase domain in absence of its crystal structure constituted the basis of development of ALK small molecule inhibitors. Here, we described normal function of the ALK receptor and its role in tumors; formation of the constitutively activated ALK fusion proteins and we reported an update of developed small molecule inhibitors of the ALK kinase activity.
Export Options
About this article
Cite this article as:
J. Tartari Carmen, Scapozza Leonardo and Gambacorti-Passerini Carlo, The ALK Gene, An Attractive Target for Inhibitor Development, Current Topics in Medicinal Chemistry 2011; 11 (11) . https://dx.doi.org/10.2174/156802611795589593
DOI https://dx.doi.org/10.2174/156802611795589593 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the JAK/STAT Signaling Pathway for Breast Cancer
Current Medicinal Chemistry Targeting Microtubules for Cancer Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Naphthalimides and Azonafides as Promising Anti-Cancer Agents
Current Medicinal Chemistry subject Index To Volume 2
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy
Current Pharmaceutical Design Recent Progress of Src Family Kinase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Strategies for Efficient Lead Structure Discovery from Natural Products
Current Medicinal Chemistry Developmental Epigenetic Programming of Caste-specific Differences in Social Insects: An Impact on Longevity
Current Aging Science Genetic and Environmental Influences on Therapeutic and Toxicity Outcomes: Studies with CYP2A6
Current Clinical Pharmacology Lamellarins, from A to Z: A Family of Anticancer Marine Pyrrole Alkaloids
Current Medicinal Chemistry - Anti-Cancer Agents Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy Hypericin Lights Up the Way for the Potential Treatment of Nasopharyngeal Cancer by Photodynamic Therapy
Current Clinical Pharmacology Anticancer Advances of Matrine and Its Derivatives
Current Pharmaceutical Design Lanthanum, Gallium and their Impact on Oxidative Stress
Current Medicinal Chemistry A Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century
Current Medicinal Chemistry Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Current Drug Delivery Recent Advances in Pharmacokinetics of Polymeric Excipients Used in Nanosized Anti-Cancer Drugs
Current Drug Metabolism